What should you know about IRTA1 immunohistochemistry?

Immunohistochemistry uses antibodies to highlight a particular protein in preserved tissue. IRTA1 is a marker that may be present in some immune-cell populations and related lymphoid conditions. A positive or negative stain is not, by itself, a complete diagnosis. The pathologist interprets the staining pattern, strength, distribution, and sample quality with the cell appearance and the rest of the laboratory report.

The result may help separate conditions that look similar under a microscope or support a suspected classification. Interpretation can be limited when the biopsy is small, damaged, or altered by earlier treatment.

Ask for the exact wording of the report and which diagnosis the stain is being used to evaluate. Review it with the haematologist or pathologist rather than treating IRTA1 as a stand-alone cancer test. A biopsy may be paired with flow cytometry, genetic testing, blood tests, or imaging when those results are needed to classify the condition and guide treatment.

The stain itself does not usually create an urgent problem because it is performed on tissue already collected. Seek prompt clinical advice for heavy bleeding from the biopsy site, increasing swelling, fever, spreading redness, severe pain, or feeling faint after a biopsy. Follow the specific wound instructions given by the team.

Why was IRTA1 tested in my sample? Is the staining pattern positive, negative, or indeterminate? Which other results are needed before the diagnosis is settled? Could the sample need review or additional tissue?